Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-06-2015 | Original Article – Clinical Oncology

Convergence with SEER database achieved by a breast cancer network: a longitudinal benchmark of 5-year relative survival

Authors: Christian O. Jacke, Ute S. Albert, Iris Reinhard, Matthias Kalder

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2015

Abstract

Purpose

To benchmark outcomes of a German breast cancer network with the Surveillance Epidemiology and End Results programme (SEER) of the USA from a longitudinal point of view.

Methods

All women receiving primary breast cancer therapy of three hospitals in a rural district of Marburg-Biedenkopf (Germany) of time intervals 1996–1997 and 2003–2004 were used to define local benchmark objects. Data from SEER-programme contributed longitudinal benchmark objects from national level (1988–2004). All benchmark objects were compared with the time-fixed benchmark reference of SEER (2004). Stage distributions and 5-year relative survival ratios were combined to estimate standardized screening-, case-mix-, work-up-, treatment- and relative overall performance index.

Results

From the entry cohort of 877 German women, 97.7 % of the patients accounted for the institutional sample (N = 857) and 65.8 % accounted for the regional sample (N = 577). Stage distributions, relative survival ratios and indices of the German breast cancer network improved over time. Developed indices converged with SEER (2004).

Conclusions

Effectiveness gap between one exemplary German breast cancer network and international benchmark defined by SEER has been closed. Reasons are manifold, and further research is recommended.

Albert U, Schulz K (2002) Aktuelle Entwicklung der Brustkrebs-Früherkennung in Deutschland und im internationalen Vergleich. Onkologe 8:1040–1052CrossRef

Albert U, Wagner U, Kalder M (2009) Breast Centers in Germany. Breast care (Basel, Switzerland) 4(4):225–230CrossRef

Autier P, Boniol M (2011) Caution needed for country-specific cancer survival. Lancet 377(9760):99–101CrossRefPubMed

Bamberg M, Glocker S (2006) Versorgungsstrukturen und Prozesse in der Onkologie. In: Hey M, Maschewsky-Schneider U (eds) Kursbuch Versorgungsforschung, Berliner Schriftenreihe Gesundheitswissenschaften. Med. Wiss. Verl.-Ges, Berlin, pp 102–109

Batzler W (2008) Krebs in Deutschland 2003–2004: Häufigkeiten und trends, 6th edn. Beiträge zur Gesundheitsberichterstattung des Bundes, Robert Koch-Institut, Berlin

Beckmann M, Bani M, Loehberg C, Hildebrandt T, Schrauder M, Wagner S, Fasching P, Lux M (2009) Are certified Breast Centers cost-effective? Breast care (Basel, Switzerland) 4(4):245–250CrossRef

Berrino F, Angelis Rd, Sant M, Rosso S, Bielska-Lasota M, Lasota M, Coebergh J, Santaquilani M (2007) Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: results of the EUROCARE-4 study. Lancet Oncol 8(9):773–783CrossRefPubMed

Bhopal R (2007) Concepts of epidemiology: an integrated introduction to the ideas, theories, principles and methods of epidemiology, repr edn. Oxford University Press, Oxford

Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, La Vecchia C (2012) The decline in breast cancer mortality in Europe: an update (to 2009). Breast (Edinburgh, Scotland) 21(1):77–82CrossRef

Brenner H, Stegmaier C, Ziegler H (2005) Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium. Ann Oncol 16(6):981–986CrossRefPubMed

Brenner H, Francisci S, Marcos-Gragera R, Verdecchia A, Gatta G, Allemani C, Ciccolallo L, Coleman MP, Sant M (2009) Long-term survival expectations of cancer patients in Europe in 2000–2002. Eur J Cancer (Oxford, England: 1990) 45(6):1028–1041CrossRef

Brucker S, Traub J, Krainick-Strobel U, Schreer I, Kreienberg R, Bamberg M, Jonat W, Wallwiener D (2005) Brustzentren: Entwicklung in Deutschland. Onkologe 11(3):285–297CrossRef

Brucker S, Bamberg M, Jonat W, Beckmann M, Kämmerle A, Kreienberg R, Wallwiener D (2009) Certification of breast centres in Germany: proof of concept for a prototypical example of quality assurance in multidisciplinary cancer care. BMC cancer 9:228CrossRefPubMedCentralPubMed

Brucker SY, Wallwiener M, Kreienberg R, Jonat W, Beckmann MW, Bamberg M, Wallwiener D, Souchon R (2011) Optimizing the quality of breast cancer care at certified german breast centers: a benchmarking analysis for 2003–2009 with a particular focus on the interdisciplinary specialty of radiation oncology. Strahlenther Onkol 187(2):89–99CrossRefPubMed

Coleman M, Quaresma M, Berrino F, Lutz J, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir H, Elwood J, Tsukuma H, Koifman S, Silva E G, Francisci S, Santaquilani M, Verdecchia A, Storm H, Young J (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9(8):730–756CrossRefPubMed

Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377(9760):127–138CrossRefPubMedCentralPubMed

Du Bois A, Misselwitz B, Wagner U, König K, Schneidewind G, Gnauert K, Jackisch C, Hoffmann G (2004) Disease-management-programm (DMP) Brustkrebs und Versorgungsstruktur bei der operativen Therapie des Mammakarzinoms in Hessen 2002. Geburtsh Frauenheilk 64:261–270CrossRef

Eisemann N, Waldmann A, Katalinic A (2013) Epidemiology of breast cancer: current figures and trends. Geburtshilfe Frauenheilkd 73(02):130–135CrossRefPubMedCentralPubMed

Engel J, Nagel G, Breuer E, Meisner C, Albert U, Strelocke K, Sauer H, Katenkamp D, Mittermayer C, Heidemann E, Schulz K, Kunath H, Lorenz W, Hölzel D (2002) Primary breast cancer therapy in six regions of Germany. Eur J Cancer 38:578–585CrossRefPubMed

Escobar P, Patrick R, Rybicki L, Weng D, Crowe J (2007) The 2003 revised TNM staging system for breast cancer: results of stage re-classification on survival and future comparisons among stage groups. Ann Surg Oncol 14(1):143–147CrossRefPubMed

Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312(25):1604–1608CrossRefPubMed

Geiss K, Meyer M, Radespiel-Tröger M, Gefeller O (2009) SURVSOFT-Software for nonparametric survival analysis. Comput Methods Programs Biomed 96(1):63–71CrossRefPubMed

Globocan Database (2008) Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) Worldwide in 2008. http://globocan.iarc.fr/

Globocan Database (2012) Estimated cancer incidence, mortality, and prevalence worldwide in 2012. http://globocan.iarc.fr/

Gondos A, Holleczek B, Arndt V, Stegmaier C, Ziegler H, Brenner H (2007) Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? Ann Oncol 18(7):1253–1259CrossRefPubMed

Gondos A, Bray F, Hakulinen T, Brenner H (2008) Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol 20(3):564–573CrossRefPubMed

Gondos A, Holleczek B, Janssen-Heijnen M, Brewster D, Bray F, Rosso S, Hakulinen T, Brenner H (2009) Model-based projections for deriving up-to-date cancer survival estimates: an international evaluation. Int J Cancer 125(11):2666–2672CrossRefPubMed

Hakulinen T (1982) Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 38(4):933–942CrossRefPubMed

Harbeck N, Kuschel B, Kiechle M (2002) Mammakarzinom: prognostische und prädiktive Faktoren. Onkologe 8:808–816CrossRef

Heil J, Gondos A, Rauch G, Marmé F, Rom J, Golatta M, Junkermann H, Sinn P, Aulmann S, Debus J, Hof H, Schütz F, Brenner H, Sohn C, Schneeweis A (2012) Outcome analysis of patients with primary breast cancer initially treated at a certified academic breast unit. Breast (Edinburgh, Scotland) 21(3):303–308CrossRef

Hiripi E, Gondos A, Emrich K, Holleczek B, Katalinic A, Luttmann S, Sirri E, Brenner H (2012) Survival from common and rare cancers in Germany in the early 21st century. Ann Oncol 23(2):472–479CrossRefPubMed

Holleczek B, Brenner H (2012) Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany. BMC cancer 12(1):317CrossRefPubMedCentralPubMed

Hölzel D, Engel J, Schubert-Fritschle G (2004) Disease-management-programm Brustkrebs. Dtsch Arztebl 101(25):A1810–A1819

Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis, Chen HS, Feuer EJ, Cronin KA (2013) SEER cancer statistics review, 1975–2009, based on November 2012 SEER data submission, posted to the SEER web site, April 2013. http://seer.cancer.gov/csr/1975_2010/

Jacke C (2013) Evaluation der Versorgungseffektivität eines zertifizierten Brustkrebszentrums im Zeitvergleich (1996–97, 2003–04). epubli GmbH, Berlin

Jacke C, Kalder M, Koller M, Wagner U, Albert U (2012a) Systematic assessment and improvement of medical data quality. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 55(11–12):1495–1503CrossRef

Jacke CO, Kalder M, Wagner U, Albert US (2012b) Valid comparisons and decisions based on clinical registers and population based cohort studies: assessing the accuracy, completeness and epidemiological relevance of a breast cancer query database. BMC Res Notes 5:700CrossRefPubMedCentralPubMed

Jacke CO, Reinhard I, Albert US (2013) Using relative survival measures for cross-sectional and longitudinal benchmarks of countries, states, and districts: the BenchRelSurv- and BenchRelSurvPlot-macros. BMC Public Health 13(1):34CrossRefPubMedCentralPubMed

Jacke CO, Kalder M, Wagner U, Albert U (2014) 5-Jahres-Überlebensvorteil von Brustkrebspatientinnen durch Abweichungen von S3-Leitlinien: Nachweis des Adhärenzparadoxons. Senologie 3:136–137

Junkermann H, Becker N, Peitgen H (2001) Concept and implementation of model projects for mammography screening in Germany. Der Radiol 41(4):328–336CrossRef

Katalinic A, Waldmann A (2012) Brustkrebs sicher und früh diagnostiziert: fast immer geheilt? Geburtsh Frauenheilk 72:278–280CrossRef

Katalinic A, Bartel C, Raspe H, Schreer I (2007) Beyond mammography screening: quality assurance in breast cancer diagnosis (The QuaMaDi project). BJC 96:157–161CrossRefPubMedCentralPubMed

Kooperationsgemeinschaft Mammographie (2010) Evaluationsbericht 2010: Ergebnisse des Mammographie-Screening-Programms in Deutschland. http://www.mammo-programm.de/cms_upload/datenpool/evaluationsbericht2010_20140220.pdf

Kreienberg R (2004) Interdisziplinäre S-3-Leitlinie für die Diagnostik und Therapie des Mammakarzinoms der Frau. Qualitätssicherung in der Onkologie, Zuckerschwerdt, Wien

Kreienberg R (2008) Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms, 1st edn. Zuckschwerdt, Germering/München

La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F (2009) Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 21(6):1323–1360CrossRefPubMed

Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C (2004) Cancer mortality in Europe, 1995–1999, and an overview of trends since 1960. Int J Cancer 110(2):155–169CrossRefPubMed

Michaelson J, Silverstein M, Sgroi D, Cheongsiatmoy J, Taghian A, Powell S, Hughes K, Comegno A, Tanabe K, Smith B (2003) The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 98(10):2133–2143CrossRefPubMed

Nonnemacher M, Weiland D, Stausberg J (2007) Datenqualität in der medizinischen Forschung: Leitlinie zum adaptiven Management von Datenqualität in Kohortenstudien und Registern. Med.-Wiss. Verl.-Ges, Berlin

Nöthen M, Böhm K (2009) Krankheitskosten, Gesundheitsberichterstattung des Bundes, vol 48. Robert-Koch-Inst, Berlin

OECD (2009) Health at a glance: OECD indicators 2009. http://www.oecdilibrary.org/content/book/health_glance-2009-en

Perry N (2001) European guidelines for quality assurance in mammography screening, 3rd edn. Europe against cancer, Office for Official Publ. of the Europe. Communities, Luxembourg

Pohar M, Stare J (2007) Making relative survival analysis relatively easy. Comput Biol Med 37(12):1741–1749CrossRefPubMed

Reinhold T, Thierfelder K, Müller-Riemenschneider F, Willich S (2009) Gesundheitsökonomische Auswirkungen der DRG-Einführung in Deutschland eine systematische Übersicht. Gesundheitswesen 71(05):306–312CrossRefPubMed

RKI (2010) Krebs in Deutschland 2007/2008: Häufigkeiten und Trends, 8th edn. Gesundheitsberichterstattung des Bundes, Berlin and Saarbrücken

RKI (2013) Krebs in Deutschland 2009/2010, 9th edn. Gesundheitsberichterstattung des Bundes, Berlin

Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology, 3rd edn. Wolters Kluwer Lippincott Williams & Wilkins, Philadelphia

Sant M, Capocaccia R, Verdecchia A, Estève J, Gatta G, Micheli A, Coleman MP, Berrino F, The EUROCARE Working Group (1998) Survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. Int J Cancer 77(5):679–683CrossRefPubMed

Sant M, Allemani C, Berrino F, Coleman M, Aareleid T, Chaplain G, Coebergh J, Colonna M, Crosignani P, Danzon A, Federico M, Gafà L, Grosclaude P, Hédelin G, Macè-Lesech J, Garcia C, Møller H, Paci E, Raverdy N, Tretarre B, Williams E (2004) Breast carcinoma survival in Europe and the United States. Cancer 100(4):715–722CrossRefPubMed

Schulz K, Albert U (2003) Stufe-3-Leitlinie: Brustkrebs-Früherkennung in Deutschland. Zuckschwerdt, München

Schulz K, Bock K, Wagner U, Albert U (2003) Nutzen und Risiken des Disease Management Programms Mamma Karzinom. In: Pfaff H, Schrappe M, Lauterbach K, Engelmann U, Halber M (eds) Gesundheitsversorgung und Disease Management: Grundlagen und Anwendungen der Versorgungsforschung. Huber, Bern, pp 243–246

SEER (2012) Surveillance, epidemiology and end results, SEER*Stat database incidence—SEER 18 regs research data + Hurricane Katrina impacted Louisiana cases, Nov 2011 Sub (1973–2009 varying): linked to county attributes—total U.S., 1969–2010 counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission.

Selbmann HK (2005) Zertifizierungsverfahren in der Onkologie. Onkologe 11:1292–1297CrossRef

Sinn H, Castro Habedank A, Fournier Dv, Bastert G, Schneeweis A (2004) Reclassification of stages leads to changes of relative survival rates: the new TNM classification for breast cancer. Geburtsh Frauenheilk 64:962–967CrossRef

Wallwiener D (2014) DGS-Tagung. 10 Jahre Zertifizierte Brustzentren (DKG/DGS): die deutsche Erfolgsgeschichte. Geburtshilfe Frauenheilkd 74(09):881–882CrossRef

Wittekind C (2005) TNM-Klassifikation maligner Tumoren, 6th edn. Springer, Heidelberg

Wöckel A, Kurzeder C, Geyer V, Novasphenny I, Wolters R, Wischnewsky M, Kreienberg R, Varga D (2010) Effects of guideline adherence in primary breast cancer: a 5-year multi-center cohort study of 3976 patients. Breast 19(2):120–127CrossRefPubMed

Title: Convergence with SEER database achieved by a breast cancer network: a longitudinal benchmark of 5-year relative survival
Authors: Christian O. Jacke
Ute S. Albert
Iris Reinhard
Matthias Kalder
Publication date: 01-06-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 6/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1879-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Convergence with SEER database achieved by a breast cancer network: a longitudinal benchmark of 5-year relative survival

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2015

High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up

Identification of FLOT2 as a novel target for microRNA-34a in melanoma

The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model

The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution

Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer

Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page